Novel therapies in SSc

Systemic sclerosis (SSc) is an autoimmune connective tissue disease that is rare and targets fibrosis and vasculopathy with autoantibodies present. There are guidelines in SSc that are evidence based and can facilitate appropriate treatment for many patients with SSc. However, there is no cure and in many patients the quality and quantity of life are significantly affected. Thus, novel therapies in SSc are warranted in order to try to prevent damage and increase quality of life and improve survival. This update will expand where the standard of care treatment in SSc may be enhanced by novel therapies and recent or ongoing trials. As few studies of Raynaud's phenomenon, digital ulcers, gastrointestinal, cardiac, renal and musculoskeletal systems in SSc are ongoing, they will not be included. This paper will concentrate on immune modification for skin involvement and interstitial lung disease and pulmonary hypertension. Potentially transformative treatments will be highlighted and where they may fit into a future improved standard of care for SSc patients.